Medtronic plc

MDT · NYSE · Healthcare

$84.21▲ +1.20%

+$1.00 today

Mkt cap $107.79B
P/E 22.6
Day $83.21 – $85.14

Confidence

High conviction

The read

Medtronic reports in-line Q4 EPS of $1.55; shares slightly up post-earnings

Medtronic's Q4 EPS came in at $1.55, marginally below the $1.56 estimate, with shares rising 0.1% post-report. Guidance tone was neutral, reflecting steady revenue growth but ongoing risks from the diabetes unit spinoff and neuromodulation recall.

Confidence note: EPS reported in-line with consensus and clear risks identified; catalyst timeline and risks well defined for actionable scenarios.

What happened

Earnings print

EPS of $1.55 was in-line with consensus estimate of $1.56, a -0.64% surprise.

Guidance

Management maintained a neutral guidance tone amid spinoff and recall uncertainties.

Price reaction

Shares rose modestly by 0.1% on the day of the earnings release.

Street narrative

Dividend growth offsets concerns about the diabetes unit spinoff; neuromodulation recall remains a risk to growth and confidence.

So what

What changed

Q4 EPS was $1.55, slightly below estimate, with neutral guidance amid spinoff and recall risks.

What the market is pricing

The 0.1% share price rise reflects cautious optimism despite in-line EPS and ongoing operational risks.

Fundamental takeaway

Maintain current view; monitor upcoming earnings and spinoff impact for growth clarity.

Next 30–90 days

Bull

36%

Spinoff proceeds smoothly, neuromodulation recall impact diminishes, enabling renewed growth acceleration.

Positive updates on diabetes unit spinoff integration by Q3 earnings.
Resolution or mitigation of neuromodulation recall issues within 90 days.

Base

39%

Steady revenue growth continues with manageable spinoff and recall headwinds, EPS growth remains moderate.

Stable guidance with no major changes in next earnings report.
No new significant recall or spinoff setbacks.

Bear

25%

Spinoff complications and recall issues intensify, pressuring growth and investor confidence, leading to earnings misses.

Negative guidance revision in next quarter.
Material delays or financial impact from spinoff or recall.

What to do

If you hold it

Hold MDT unless next-quarter guidance falls below current expectations or recall issues worsen materially.

If you're watching

Consider entry if upcoming earnings show clear spinoff progress and stable recall resolution; avoid if guidance weakens or new risks emerge.

Keep on your radar

Next earnings report expected by Q3 2026 for spinoff and guidance updates.
Management commentary on diabetes unit spinoff execution progress.
Neuromodulation recall status and any regulatory developments.
Dividend sustainability given 76% payout ratio and cash flow trends.